Cellular immunity against human papillomavirus associated cervical cancer

Seminars in Virology

Volumn 7, Issue 2, 1996, Pages 117-123

  Kast, W Martin ^a   Feltkamp, Mariet C W ^b   Ressing, Maaike E ^b   Vierboom, Michel P M ^b   Brandt, Remco M P ^b   Melief, Cornelis J M ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Human papillomavirus; T cell; Tumor immunology; Vaccine; Viral immunology

Indexed keywords

CANCER VACCINE; HYBRID PROTEIN; VIRUS PROTEIN;

CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; FEMALE; HELPER CELL; HOST RESISTANCE; HUMAN; NONHUMAN; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

ANIMALIA; CANCER VIRUS; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES;

EID: 0029961772     PISSN: 10445773     EISSN: None     Source Type: Journal    
DOI: 10.1006/smvy.1996.0015     Document Type: Review

References (94)

1. Zur Hausen H (1991) Viruses in human cancer. Science 254:1167-1172
2. Chan SY, Delius H, Halpern AL, Bernard HU (1995) Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny and taxonomy. J Virol 69:3074-3083
3. Villiers EM (1989) Hererogenicity of the human papillomavirus group. J Virol 63:4898-4903
4. Van den Brule AJC, Walboomers JMM, Du Maine M, Kenemans P, Meijer CJLM (1991) Difference in prevalence of HPV genotype in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer 48:404-408
5. Resnick RM, Cornelissen MTE, Wright DK, Eichinger GH, Fox HS, ter Schegget J, Manos MM (1990) Detection and typing of human papillomavirus in archival cancer specimens by DNA amplification. J Natl Cancer Inst 82:1477-1482
6. Seedorf K, Krammer G, Durst M, Suhai S, Rowekamp WG (1985) Human papillomavirus type 16 DNA sequence. Virology 145:181-185
7. Durst M, Gissman L, Ikenberg H, Zur Hausen H (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci 80:3812-3815
8. Cornelissen MTE, Bots T, Briet MA, Jebbink MF, Struyk APHB, van den Tweel JG, Greer CE, Smits HL, ter Schegget J (1992) Detection of human papillomavirus types by polymerase chain reaction and the differentiation between high-risk and low-risk cervical lesions. Virchows Archiv B Cell Pathol 62:167-171
9. De Villiers EM, Wagner D, Schneider A, Wesch H, Munz F, Miklaw H, Zur Hausen H (1992) Human pappillomavirus DNA in women without and with cytological abnormalities: results of a five year follow-up study. Gynecol Oncol 44:33-39
10. Zunzunegui MV, King MC, Coria CF, Charlet J (1986) Male influences on cervical cancer risk. Am J Epidemiol 123:302-307
11. Azocar J, Abad SMJ, Acosta R, Gallegos M, Pifano E, Blanch R, Kramar A (1990) Prevalence of cervical dysplasia and HPV infection according to sexual behavior. Int J Cancer 45:622-625
12. Durst M, Glitz D, Schneider A, Zur Hausen H (1992) Human papillomavirus type 16 (HPV16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology 189:132-140
13. Stoler MH, Rhodes CH, Whitbeck A, Wolinsky SM, Chow LT, Broker TR (1992) Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Human Pathol 23:117-128
14. Vogelstein B, Kinzler RW (1992) p53 function and dysfunction. Cell 70:523-526
15. Weinberg RA (1991) Tumor suppressor genes. Science 254:1138-1146
16. Smotkin D, Wettstein FO (1986) Transcription of HPV16 early genes in a cervical cancer and a cervical cancer derived cell line, and the identification of the E7 protein. Proc Natl Acad Sci 83:4680-4686
17. Baker CJ, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM (1987) Structural and transcriptional analysis of HPV16 sequences in cervical carcinoma cells. J Virol 61:962-970
18. Von Knebel Doeberitz M, Oltersdorf T, Schwarz E, Gissman L (1988) Correlation to modified human papillomavirus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 48:3780-3786
19. Crook T, Morgenstern JP, Crawford L, Banks L (1989) Continued expression of HPV16 E7 is required for maintenance of the transformed phenotype of cells co-transfected with HPV16 plus EJ ras. EMBO J 8:513-519
20. Zur Hausen H (1991) Human papillomavirus in the pathogenesis of anogenital cancer. Virology 184:9-13
21. June CH, Bluestone JA, Nadler LM, Thompson CB (1994) The B7 and CD28 receptor families. Immunol Today 15:321-331
22. Rogozinsky TT, Jablonska , Jazabek-Chorzelska M (1988) Role of cell-mediated immunity in spontaneous regression of planar warts. Int J Dermat 27:322-326
23. Ferenzy A, Mitoa M, Nagai N, Silverstein SJ, Crum CP (1995) Latent papillomavirus and recurring genital warts. N Engl J Med 313:784-788
24. Benton C, Shahidulla H, Hunter J (1992) Human papillomavirus in the immunosuppresssed. Papillomavirus Report 3:23-26
25. Fuchs PG, Pfister H (1990) Papillomaviruses in epidermodysplasia verruciformis. Papillomavirus report 1:1-4
26. Berger TG, Sawchuk WS, Leonardi C, Langenberg A, Tappero J, LeBoit PE (1991) Epidermodysplasia verruciformis-associated papillomavirus infection complicating HIV disease. Br J Dermat 124:79-83
27. Kiviat N, Rompalo A, Bowden R, Galloway D, Holmes KK, Corey L, Roberts PL, Stamm WE (1990) Anal human papillomavirus infection among HIV-seropositive and negative men. J Infect Dis 162:358-361
28. Laga M, Icenogle JP, Mercella R, Manoka AT (1992) Genital papillomavirus infection and cervical dysplasia, opportunistic complications of HIV infections. Int J Cancer 50:454-8
29. Schafer A, Friedmann W, Mielke M, Schwatlander B, Koch MA (1991) The increased frequency of cervical dysplasia in women with HIV is related to the degree of immunosuppression. Am J Obstet Gynecol 164:593-599
30. Barr BBB, Benton EC, McLaren K, Bunney H, Smith IW, Blessing K, Hunter JAA (1989) Human papillomavirus infection and skin cancer in renal allograft recipients. Lancet 1:124-128
31. Halpert R, Fruchter RG, Seclus A, Butt K, Boyce JG, Sillman FH (1985) HPV and lower genital tract neoplasia in renal transplant recipients. Obstet Gynecol 68:251-258
32. Alloub MI, Barr BBB, McLaren KM, Smith IW, Bunney MH, Smart GE (1989) Human papillomavirus infection and cervical intraepithelial dysplasia in women with renal alografts. BMJ 298:153-156
33. Gregoire L, Lawrence WD, Kukuruga D (1994) Association between HLA-DQB1 alleles and risk for cervical cancer in African-American woman. Int J Cancer 57:504-510
34. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM (1993) HLA DR-DQ disease associations in hispanic cervical carcinoma are human papillomavirus type-specific. Nature Genet 6:157-162
35. Wank R, Thomssen C (1991) High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature 352:723-725
36. Bouwes Bavinck JN, Gissman L, Claas FJH, van der Woude FJ, Persijn GG, Ter Schegget J, Vermeer BJ, Jochmus I, Muller M, Steger G (1993) Relation between skin cancer, humoral responses of human papillomaviruses, and MHC class II molecules in renal transplant patients. J Immunol 11:1579-1586
37. Bouwes Bavinck JN, Koote AM, van der Woude FJ, Vandenbroucke JP, Vermeer BJ, Claas FHJ (1991) On a possible protective effect of HLA-A1 against skin cancer and keratotic skin lesion in renal transplantation recipients. J Invest Dermatol 97:269-272
38. Apple RJ, Becker TM, Wheeler CM, Erlich HA (1995) Comparison of the human leucocyte antigen DR-DQ disease associations with cervical dysplasia and invasive cervical carcinoma. J Natl Cancer Inst 87:427-436
39. Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS (1995) Association between HLA DQB1*03 and cervical intra-epithelial neoplasia. Molec Med 2:161-171
40. Ellis JRM, Keating PJ, Baird J, Hounsell EF, Renouf DV, Rowe M, Hopkins D, Duggan-Keen MF, Bartholomew JS, Young LS, Stern PL (1995) The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nature Med 1:464-470
41. Glew SS, Duggan-Keen M, Ghosh AK, Ivenson A, Sinnott P, Davidson J, Stern PL (1993) Lack of association of HLA polymorphisms with HPV-related cervical cancer. Hum Immunol 37:157-164
42. Glew SS, Stern PL, Davidson JA, Dyer PA (1992) HLA antigens and cervical carcinoma. Nature 356:22-25
43. Connor ME, Stern PL (1990) Loss of MHC class I expression in cervical carcinomas. Int J Cancer 46:1029-1037
44. Cromme FV, Meijer CJLM, Snijders PJF, Uyterlinde A, Kenemans P, Helmerhorst T, Stern PL, Van den Brule AJC, Walboomers JMM (1993) Analysis of MHC class I and II expression in relation to HPV genotypes in premalignant and malignant cervical lesions. Br J Cancer 67:1372-1380
45. Connor ME, Davidson SE, Stern PL, Arrand JR, West CML (1993) Evaluation of multiple biological parameters in cervical carcinoma: high macrophage infiltration of HPV-associated tumors. Int J Gynecol Cancer 3:103-109
46. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJLM, Walboomers JMM (1994) Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 179:335-340
47. Cromme FV, Helmerhorst TJ, Stukart MJ, Meijer CJLM (1994) Differences in MHC and TAP expression in cervical cancer lymph node metastases as compared with the primary tumors. Br J Cancer 69:1176-1181
48. Jochmus I, Durst M, Reid R, Altmann A, Bijward KE, Gissman L, Jenson AB (1993) Major histocompatibility complex and human papillomavirus type 16 E7 expression in high grade vulvar lesions. Hum Pathol 24:519-524
49. Coleman N, Stanley MA (1994) Analysis of HLA-DR expression on keratinocytes in cervical neoplasia. Int J Cancer 56:314-319
50. Glew SS, Duggan-Keen M, Cabrera T, Stern PL (1992) HLA class II antigen expression in human papillomavirus-associated cervical cancer. Cancer Res 52:4009-4016
51. Bal V, Mclndoe A, Denton G, Hudson D, Lombardi G, Lamb J, Lechler R (1990) Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol 20:1893-1897
52. Powrie F, Coffman RL (1993) Cytokine regulation of T cell function: potential for therapeutic intervention. Immunol Today 14:270-274
53. Paul WE, Seder RA (1994) Lymphocyte responses and cytokines. Cell 76:241-251
54. Warhol MJ, Gee B (1989) The expression of histocompatibility antigen HLA-DR in cervical squamous epithelium infected with human papillomavirus. Mod Pathol 2:101-104
55. Tay SK, Jenkins D, Maddox P, Hog N, Singer A (1987) Tissue macrophage response in human papillomavirus infection and cervical intraepithelial neoplasia. Br J Obstet Gynecol 94:1094-1097
56. Tay SK, Jenkins D, Maddox P, Singer A (1987) Lymphophenotypes in cervical intraepithelial neoplasia and human papillomavirus infection. Br J Obstet Gynecol 94:16-21
57. McArdle JP, Muller K (1986) Quantative assessment of Langerhans' cells in human cervical intraepithelial neoplasia and wart infection. Am J Gynecol 154:509-515
58. Hughes RG, Norval M, Howie SEM (1988) Expression of MHC class II antigens by Langerhans cells in cervical intraepithelial neoplasia. J Clin Pathol 41:253-259
59. Viac J, Guerin-Reverchon Y, Chardonnet Y, Bremond A (1990) Langerhans cells and epithelial cell modifications in cervical intraepithelial neoplasia: correlation with human papillomavirus infection. Immunobiol 180:328-338
60. Lethinen M, Rantala I, Toivonen A, Luoto H, Aine R, Lauslathi K, Ylaoutinen A, Rompannen U, Paavonen J (1993) Depletion of Langerhans cells in cervical HPV infection is associated with replication of the virus. Apmis 101:833-837
61. Morelli AE, Sananes C, Di PG, Paredes A, Fanbom L (1993) Relationship between types of human papillomavirus and Langerhans' cells in cervical condylomata and intraepithelial neoplasia. J Clin Pathol 99:200-206
62. Bostrom SG, Hart WR (1981) Carcinomas of the cervix with intense stromal eosinophila. Cancer 47:2887-2893
63. McLean CS, Sterlin JS, Mowat J, Nash AA, Stanley MA (1993) Delayed type hypersensitivity response to the human papillomavirus type 16 E7 protein in a mouse model. J Gen Virol 74:239-245
64. Chambers MA, Stacey SN, Arrand JR, Stanley MA (1994) Delayed type hypersensitivity response to human papillomavirus type 16 E6 protein in a mouse model. J Gen Virol 75:165-169
65. Chambers MA, Wei Z, Coleman N, Nash AA, Stanley MA (1994) 'Natural' administration of human papillomavirus type 16 E7 protein to immunocompetent mice results in antigen-specific sensitization or sustained unresponsiveness. Eur J Immunol 24:738-745
66. Davies DH, Hill CM, Rothbard JB, Chain BM (1990) Definition of T helper cell determinants in the major capsid protein of human papillomavirus type 16. J Gen Virol 71:2691-2698
67. Shepard PS, Tran TT, Rowe AJ, Cridland JC, Comerford SA, Chapman MG, Rayfiels LS (1992) T cell responses to the human papillomavirus type 16 E7 protein in mice of different haplotypes. J Gen Virol 73:1269-1274
68. Tindle RW, Fernando GJP, Sterling JC, Frazer IH (1991) A 'public' T helper epitope of the E7 transforming protein of human papillomavirus 16 provide a cognate help for several E7 B cell epitopes from cervical cancer-associated human papillomvirus genotypes. Proc Natl Acad Sci USA 88:5587-5591
69. Vandebriel RJ, van der Kolk M, Geerse L, Steerenberg PA, Krul MRL (1995) A helper T cell epitope of the E7 protein of human papillomavirus type 16 in BALB/c mice. Virus Res 37:13-22
70. Zhou J, Sun XY, Davies H, Crawford L, Park D, Frazer IH (1992) Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles. Virology 185:592-599
71. Chen L, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE (1991) Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci 88:110-114
72. Chen L, Mizuno MT, Singhal MC, Hu SL, Galoway DA, Hellstrom I, Hellstrom KE (1992) Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 148:2617-2621
73. Stauss HJ, Davies H, Sadnikova E, Chain B, Horowitz N, Sinclair C (1992) Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T cell epitopes in human papillomavirus. Proc Natl Acad Sci 89:7871-7875
74. Feltkamp MCW, Smits HL, Vierboom MPM, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJM, Kast WM (1993) Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23:2242-2249
75. Ossevoort MA, Feltkamp MCW, van Veen KJH, Melief CJM, Kast WM (1995) Dendritic cells as carriers for a cytotoxic T lymphocyte epitope based peptide vaccine in protection against a human papillomavirus type 16 induced tumor. J Immunotherapy 18:86-94
76. Feltkamp MCW, Vreugdenhil GR, Vierboom MPM, Ras E, van der Burg SH, ter Schegget J, Melief CJM, Kast WM (1995) CTL raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 25:2638-2642
77. Sadnikova E, Zhu X, Collins S, Zhou J, Vousden K, Crawford L, Beverly P, Stauss HJ (1994) Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papillomavirus E7 protein. Int Immunol 6:289-296
78. Gao L, Chain B, Sinclair C, Crawford L, Zhou J, Morris J, Zhu X, Stauss HJ (1994) Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector. J Gen Virol 75:157-164
79. Lipford GB, Bauer S, Wagner H, Heeg K (1995) Peptide engineering allows T cell vaccination against human papillomavirus tumor antigen E6. Immunology 84:298-303
80. Meneguzzi G, Cerni C, Kieny MP, Lathe R (1991) Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia vectors expressing E6 and E7. Virology 181:62-69
81. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter J, McGowan P, Linsley PS (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093-1102
82. Mayordomo JI, Zorina T, Storkus WJ, Celluzi C, Falo, LD, Melief CJM, Ildstad ST, Kast WM, De Leo A, Lotze MT (1995) Bone marrow-derived dendritic cells pulsed with tumor peptides. Effectively treat established murine tumors. Nature Med 1:1297-1302
83. Hopfl R, Sandbichler M, Sepp N, Heim K, Muller-Holzner E, Wartusch B, Dapunt O, Jochmus-Kudielka I, Ter Meulen J, Gissman L, Fritsch P (1991) Skin test for HPV type 16 proteins in cervical intraepithelial neoplasia. Lancet 337:373-374
84. Strang G, Hickling JK, McIndoe GA, Howland K, Wilkinson D, Ikeda H, Rothbard JB (1990) Human T cell responses to human papillomavirus type 16 L1 and E6 synthetic peptides: identification of T cell derminants, HLA-DR restriction and virus type specificity. J Gen Virol 71:423-431
85. Altmann A, Jochmus-Kudielka I, Franf R, Gausepohl H, Moeblus U, Gissmann L, Meuer SC (1992) Definition of immunogenic determinants of the human papillomavirus type 16 nucleoprotein E7. Eur J Cancer 28:326-333
86. Cubie HA, Norval M, Crawford L, Crook T (1989) Lymphoproliferative response to fusion proteins of human papillomavirus in patients with cervical intraepithelial neoplasia. Epidermiol Infect 103:625-632
87. Comerford SA, McCance DJ, Dougan G, Tite JP (1991) Identification of T- and B-cell epitopes of the E7 protein of human papillomavirus type 16. J Virol 65:4681-4690
88. Kadish AS, Romney SL, Ledwidge R, Tindle R, Fernando GJP, Zee SY, van Ranst MA, Burk RD (1994) Cell-mediated immune response to E7 peptides of HPV16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific. J Gen Virol 75:2277-2284
89. Kast WM, Brandt RMP, Sidney J, Drijfhout JW, Kubo RT, Grey HM, Melief CJM, Sette A (1994) Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type E6 and E7 proteins. J Immunol 152:3904-3912
90. Central data analysis committee (1991) Allelel frequencies. Section 6.3 splits combined (Five loci), in the Data Book of the 11th International Histocompatibility Workshop, Yokohama, Japan p.807
91. Kast WM, Brandt RMP, Drijfhout JW, Melief CJM (1993) Human leucocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother 14:115-120
92. Ressing ME, Sette A, Brandt RMP, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJM, Kast WM (1995) Human CTL epitopes encoded by human papillomavirus type E6 and E7 identified through in-vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154:5934-5943
93. Ressing ME, Van Driel WJ, Celis E, Sette A, Brandt, RMP, Hartman M, Anholts JDH, Schreuder GMT, Ter Harmsel WB, Fleuren GJ, Trimbos BJ, Kast WM, Melief CJM (1996) Occasional memory cytotoxic T cell responses of patients with human papillomavirus type 16-positive cervical lesions against an HLA-A* 0201-restricted E7-encoded epitope. Cancer Res, in press
94. Bartholomew JS, Stacey SN, Coles B, Burt DJ, Arrand JR, Stern PL (1994) Identification of a naturally processed HlA-A*0201-restricted viral peptide from cells expressing human papillomavirus type 16 E6 oncoprotein. Eur J Immunol 24:3175-3179